Pharma Journalist -

AstraZeneca’s Tagrisso (osimertinib)​ has been approved in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm)…
Read More...

Pfizer Inc. announced that it is voluntarily withdrawing all lots of OXBRYTA (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is…
Read More...

Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, announced a new strategic…
Read More...

The Ministry of Health, Labour and Welfare Japan has approved Kisunla (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion), Eli Lilly and Company's Alzheimer's…
Read More...

Vanda Pharmaceuticals Inc. (Vanda) provided an update on its tradipitant development program. On September 18, 2024, the U.S. Food and Drug Administration (FDA) declined to approve…
Read More...

Papillon Therapeutics Inc., a clinical-stage biotechnology company advancing a pipeline of multi-systemic genetic medicines directed at the underlying causes of inherited disease,…
Read More...

Merck, known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination…
Read More...

BeiGene, Ltd. announced that the Israeli Ministry of Health (IL MOH) has approved TEVIMBRA (tislelizumab) as monotherapy for the treatment of adult patients with unresectable or…
Read More...

Prepare for the definitive meeting dedicated to refining analytics to ensure the swift progression of highly efficacious products through IND and clinical trials, ultimately securing…
Read More...

Valneva SE, a specialty vaccine company, announced that it has submitted label extension applications to the European Medicines Agency (EMA) and Health Canada to potentially expand the…
Read More...